Carvacrol enhances the sensitıvity of cetuximab in lung cancer cells through inducing apoptosis and cell cycle arrest
[ X ]
Tarih
2025
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Bangladesh Pharmacological Soc
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
The intention of this work was to analyze that carvacrol could enhance cancer-inhibiting potency of cetuximab (monoclonal antibody) in lung cancer cells. The combination of cetuximab and carvacrol was found to co-operatively suppress cell proliferation by enhancing apoptosis and inducing cell cycle arrest in A-549 and H1299 cells. Furthermore, the combination therapy triggered cell death by inducing membrane disruption. The most effective combinations were IC10 cetuximab + IC10 carvacrol for A-549 and IC20 cetuximab + IC10 carvacrol for H1299 (CI = 2.0). LDH activity increased by 101% in A-549 and 239% in H1299 (p<0.05). Caspase-3 activity rose by 1.6-fold in A549 and 1.4-fold in H1299 (p<0.05). The combination decreased PCNA, topoisomerase II-alpha, and cyclins D1, D2, E, A, and B (p<0.05). Overall, the combination of carvacrol and cetuximab appears to enhance anti-cancer efficacy and may significantly improve therapeutic outcomes in lung cancer cells.
Açıklama
Anahtar Kelimeler
Growth-Factor Receptor, Monoclonal-Antibody, Neck-Cancer, Chemical-Composition, Essential Oils, Egfr, Expression, Antioxidant, Chemotherapy, Inhibition
Kaynak
Bangladesh Journal of Pharmacology
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
20
Sayı
1
